99mTc-labeling and molecular modeling of short dipeptide glycyl-l-proline



Glycyl-l-proline (Gly-l-Pro) is the main degradation product of collagen and is a good diagnostic tool in various pathological conditions. The aim of this work was to prepare dipeptide Gly-l-Pro labeled with 99mTc. Complex preparation was carried out under alkaline reaction conditions and its stability was assessed 10 and 120 min after preparation. The formation of two types of complex compounds was observed. High-performance liquid chromatography, paper electrophoresis, paper chromatography and thin layer chromatography were employed to monitor the formation of different complexes. Molecular modeling (semi-empirical method) was used to design their structure and composition. First complex cI with formula [TcO(Gly-l-Pro)]−1 is unstable. After 120 min cI is completely transformed to complex cII with formula Tc(Gly-l-Pro)3.


99mTc Dipeptide Glycyl-l-proline Molecular modeling 



This work was funded by grand from the Ministry of Education of the Slovak Republic number 1/0003/08.


  1. 1.
    Signore A, Annavazzi A, Chianelli M et al (2001) Eur J Nucl Med 28:1555–1556CrossRefGoogle Scholar
  2. 2.
    Blok D, Vermeij P, Pauwels EJK (1999) Eur J Nucl Med 26:1511–1519CrossRefGoogle Scholar
  3. 3.
    Langer M, Bella R, Garcia-Garayova E et al (2001) Bioconjug Chem 12:1028–1034CrossRefGoogle Scholar
  4. 4.
    Decristoforo C, Mather SJ (1999) Bioconjug Chem 10:431–438CrossRefGoogle Scholar
  5. 5.
    Gariepy J, Remy S, Zhang XG et al (2002) Bioconjug Chem 13:679–684CrossRefGoogle Scholar
  6. 6.
    Zhu Z, Wang Y, Zhang Y (2001) Nucl Med Biol 28:703–708CrossRefGoogle Scholar
  7. 7.
    Liu S, Edwards DS (1999) Chem Rev 99:2235–2268CrossRefGoogle Scholar
  8. 8.
    Sassi ML (2001) Carboxyterminal degradation products of type I collagen. Oulu University Press, Oulu. ISBN 951-42-6491-6Google Scholar
  9. 9.
    Reiser KM, Amigable MA, Last JA (1992) J Biol Chem 267:24207–24216Google Scholar
  10. 10.
    Hadley JC, Meek KM, Malik NS (1998) Glycoconjug J 15:835–840CrossRefGoogle Scholar
  11. 11.
    Le J, Perier C, Peyroche S et al (1998) Amino Acids 17:315–322CrossRefGoogle Scholar
  12. 12.
    Lullo GA, Sweeney SM, Korkko J et al (2002) J Biol Chem 277:4223–4231CrossRefGoogle Scholar
  13. 13.
    Chruscinska E, Garribba E, Micera G (1999) J Chem Res (S) 3:240–241CrossRefGoogle Scholar
  14. 14.
    Kittl WS, Rode BM (1981) Inorg Chim Acta 55:21–27CrossRefGoogle Scholar
  15. 15.
    Kotluv WL, Fried M, Gurd FRN (1959) J Am Chem Soc 82:233–241Google Scholar
  16. 16.
    Martin RB, Chamberlin M, Edsall JT (1959) J Am Chem Soc 82:495–508CrossRefGoogle Scholar
  17. 17.
    Benkovsky I, Stanik R (2008) J Radioanal Nucl Chem 280:63–68CrossRefGoogle Scholar
  18. 18.
    Stalteri MA, Bansal S, Hider R et al (1999) Bioconjug Chem 10:130–136CrossRefGoogle Scholar
  19. 19.
    Cantorias MV, Howell RC, Todaro L et al (2007) Inorg Chem 46:7326–7340CrossRefGoogle Scholar
  20. 20.
    Gano L, Patricio L, Castanheira I (1989) J Radioanal Nucl Chem 132:171–178CrossRefGoogle Scholar
  21. 21.
    Kothari K, Pillai MRA, Unni PR et al (1999) Appl Radiat Isot 51:43–49CrossRefGoogle Scholar
  22. 22.
    Park JY, Lee TS, Choi TH et al (2007) Nucl Med Biol 34:1029–1036CrossRefGoogle Scholar
  23. 23.
    Jovanovic V, Maksin T, Konstantinovska D et al (1980) J Radioanal Chem 59:239–243CrossRefGoogle Scholar
  24. 24.
    Zolle I (2007) Technetium-99m pharmaceuticals. Springer, Berlin. ISBN-10-3-540-33989-2Google Scholar
  25. 25.
    Fis M, Brabec V, Dragoun O et al (1986) Int J Radiat Appl Instrum A. Appl Radiat Isot 37:1213–1218CrossRefGoogle Scholar
  26. 26.
    Yoshihara K, Omori T (1996) Technetium and rhenium. Springer, Berlin. ISBN 3-540-59469-8Google Scholar
  27. 27.
    Hashimoto K, Kamal WHBBW, Matsuoka H (2005) J Nucl Radiochem Sci 6:193–196Google Scholar
  28. 28.
    Reichert DE, Welch MJ (2001) Coord Chem Rev 212:111–131CrossRefGoogle Scholar
  29. 29.
    Comba P, Daubinet A, Bodo M et al (2006) J Organomet Chem 691:2495–2502CrossRefGoogle Scholar
  30. 30.
    Boudreau RJ, Mertz E (1997) Nucl Med Biol 24:395–398CrossRefGoogle Scholar
  31. 31.
    Bandoli G, Clemente DA, Mazzi U et al (1978) Acta Crysallogr B34:3359–3360CrossRefGoogle Scholar
  32. 32.
    Jurisson JS, Dancey K, McPartlin M et al (1984) Dtsch Inorg Chem 23:4743–4748CrossRefGoogle Scholar
  33. 33.
    Abram U, Abram S, Dilworth JR (1996) Acta Crystallogr C52:605–607Google Scholar
  34. 34.
    Bryan JC, Cotton FA, Daniels LM et al (1995) Inorg Chem 34:1875–1883CrossRefGoogle Scholar
  35. 35.
    Archer CM, Dilworth JR, Thompson RM et al (1993) J Chem Soc, Dalton Trans 3:461–466CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2010

Authors and Affiliations

  1. 1.Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of PharmacyComenius UniversityBratislavaSlovakia

Personalised recommendations